KPRX - Kiora jumps 60% as regulators clear mid-stage trial for eye disease candidate
- Nano-cap stock Kiora Pharmaceuticals ( NASDAQ: KPRX ) added ~59% pre-market Tuesday after announcing regulatory clearance for its investigational new drug (IND) application targeted at eye disease candidate KIO-101.
- With the IND, the company has sought to start a Phase 2 trial for KIO-101 in the treatment of Ocular Presentation of Rheumatoid Arthritis and other autoimmune diseases (OPRA+) (eye manifestations seen in autoimmune diseases including RA)).
- Kiora ( KPRX ) expects to start the multi-center, randomized, double-masked trial in Australia during H1 2023 to test two concentrations of KIO-101, 0.15 % and 0.30 %, in approximately 120 patients.
- "Ocular surface disease is the most common non-joint manifestation of patients living with Rheumatoid Arthritis (RA) as well as other common autoimmune diseases," Chief Executive Eric Daniels explained.
- He added that a topical eye drop, KIO-101, has established its proof-of-concept in previous ocular inflammation clinical studies.
- Encinitas, California-based Kiora ( KPRX ) targets inherited and age-related degenerative retinal diseases with its lead asset KIO-301 which is currently undergoing an early-stage trial for retinitis pigmentosa.
For further details see:
Kiora jumps 60% as regulators clear mid-stage trial for eye disease candidate